Developing breakthrough AXL therapeutics to improve patients’ lives

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

BerGenBio’s lead candidate, bemcentinib, is in Phase II clinical testing in patients with NSCLC, AML and COVID-19. As of the end of 2021, bemcentinib had been studied in over 600 patients, demonstrating its safety as a monotherapy and in combination with chemotherapy and immune checkpoint inhibition. This large safety database positions us well to advance the development of bemcentinib towards the market. Clinical data generated with bemcentinib in multiple Phase I and Phase II trials to date, confirm its potential utility as a therapy in cancer and for the treatment of COVID-19. Based on preclinical and early clinical data, we also believe bemcentinib may have the ability to enhance outcomes when combined with immunotherapy in NSCLC. Taken together, our initial data form the basis of BerGenBio’s preparations for the late-stage clinical strategy for bemcentinib.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).